Merck & Co., Inc. (NYSE:MRK) Shares Sold by Monument Capital Management


Share on StockTwits

Monument Capital Management trimmed its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 91.3% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,630 shares of the company’s stock after selling 27,752 shares during the quarter. Monument Capital Management’s holdings in Merck & Co., Inc. were worth $203,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of MRK. Wealth Alliance lifted its holdings in shares of Merck & Co., Inc. by 9.6% in the 3rd quarter. Wealth Alliance now owns 21,155 shares of the company’s stock valued at $1,755,000 after buying an additional 1,845 shares during the period. OLD Mission Capital LLC acquired a new stake in shares of Merck & Co., Inc. in the 3rd quarter valued at approximately $247,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 90.2% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 102,974 shares of the company’s stock valued at $8,542,000 after buying an additional 48,825 shares during the period. Westover Capital Advisors LLC lifted its holdings in shares of Merck & Co., Inc. by 28.5% in the 3rd quarter. Westover Capital Advisors LLC now owns 13,821 shares of the company’s stock valued at $1,146,000 after buying an additional 3,066 shares during the period. Finally, IHT Wealth Management LLC increased its stake in Merck & Co., Inc. by 2.5% in the 3rd quarter. IHT Wealth Management LLC now owns 25,452 shares of the company’s stock valued at $2,111,000 after purchasing an additional 616 shares in the last quarter. 72.86% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. stock opened at $76.22 on Tuesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30. The stock has a fifty day moving average of $75.50 and a two-hundred day moving average of $78.85. The company has a market capitalization of $192.87 billion, a price-to-earnings ratio of 16.86, a PEG ratio of 1.89 and a beta of 0.43. Merck & Co., Inc. has a fifty-two week low of $71.71 and a fifty-two week high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Wednesday, February 3rd. The company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.06). The company had revenue of $12.51 billion for the quarter, compared to analysts’ expectations of $12.65 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.16 EPS. On average, analysts forecast that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 7th. Shareholders of record on Monday, March 15th were given a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.41%. The ex-dividend date was Friday, March 12th. Merck & Co., Inc.’s payout ratio is 50.10%.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $95.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as and vaccine products.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.